Randomized comparison of daclatasvir plus asunaprevir versus telaprevir plus peginterferon/ribavirin in Japanese hepatitis C virus patients

摘要

Background and Aim: Daclatasvir combined with asunaprevir is the first all-oral, ribavirin-free treatment of hepatitis C virus genotype 1b infection in Japan. This study compared the efficacy and safety of daclatasvir plus asunaprevir versus telaprevir plus peginterferon/ribavirin in Japanese treatment-naive patients infected with hepatitis C virus genotype 1b.